Population mortality affects long-term follow-up of AlloHCT

Population mortality affects long-term follow-up of AlloHCT

(HealthDay)—For older patients undergoing allogeneic hematopoietic cell transplantation (alloHCT), a considerable part of total nonrelapse mortality (NRM) is attributable to population mortality, according to a study recently published in Leukemia.

Johannes Schetelig, M.D., from the Universitaetsklinikum Dresden in Germany, and colleagues examined the contribution of relapse-related, treatment-related, and population factors on late patient mortality after alloHCT for or secondary acute myeloid leukemia. Data from 6,434 were retrospectively studied.

The researchers found that the probability of overall survival was 53 and 35 percent at two and 10 years after alloHCT, respectively. The probability of survival was 88 and 63 percent at five years from the two-year landmark for patients aged <45 years and ≥65 years at alloHCT, respectively. The cumulative incidence of NRM was 7 percent for patients <45 years at transplant and increased to 25 percent for patients aged ≥65 years. Thirty-one percent of NRM-related deaths could be attributed to population mortality for . Post-alloHCT long-term survival was favorable, but excess mortality risk was seen for all age groups compared with the general population.

"We propose that the consideration of population should become standard, especially when long-term follow-up data after alloHCT are reported for elderly patients," the authors write.

More information: Abstract/Full Text

Journal information: Leukemia

Copyright © 2019 HealthDay. All rights reserved.

Citation: Population mortality affects long-term follow-up of AlloHCT (2019, April 3) retrieved 27 September 2023 from https://medicalxpress.com/news/2019-04-population-mortality-affects-long-term-follow-up.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Team develops personalized prediction model for patients with MDS


Feedback to editors